PowerShares Dynamic Retail ETF (PMR)
NYSEArca - NYSEArca Delayed Price. Currency in USD
- PR Newswire•11 hours ago
PharmaMar (PHM.V) has announced today that the European Medicines Agency (EMA) has accepted to assess the Marketing Authorization Application (MAA) for Aplidin® (plitidepsin) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM). PharmaMar submitted the above mentioned application for the antitumor drug of marine origin, Aplidin®, in combination with dexamethasone given the positive results obtained from the ADMYRE study. Plitidepsin could be a therapeutic alternative for patients suffering from relapsed and/or refractory multiple myeloma.
- PR Newswire•5 days ago
MADRID, October 24, 2016 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the opening of a new affiliate in Austria with the aim of reinforcing the presence of the Company within Europe, one of ...